Preliminary phytochemical screening and antimicrobial activity of Samanea saman

Samanea saman is a tropically distributed medicinal plant. Antimicrobial activity of aqueous extract of this plant was investigated by Well-diffusion method against three organisms: Escherichia coli, Staphylococcus aureus and Candida albicans. The plant extract showed inhibitory activity against all the tested organisms. Five mg/ml inhibited the growth of E. coli but slightly higher concentration of 10 mg/mL was necessary to show inhibition against S. aureus and C. albicans. Phytochemical screening of the plant revealed the presence of tannins, flavonoides, saponins, steroids, cardiac glycosides and terpenoids. The study scientifically validates the use of plant in traditional medicine

Mirror, mirror on the wall: which microbiomes will help heal them all?

BACKGROUND: Clinicians have known for centuries that there is substantial variability between patients in their response to medications—some individuals exhibit a miraculous recovery while others fail to respond at all. Still others experience dangerous side effects. The hunt for the factors responsible for this variation has been aided by the ability to sequence the human genome, but this just provides part of the picture. Here, we discuss the emerging field of study focused on the human microbiome and how it may help to better predict drug response and improve the treatment of human disease. DISCUSSION: Various clinical disciplines characterize drug response using either continuous or categorical descriptors that are then correlated to environmental and genetic risk factors. However, these approaches typically ignore the microbiome, which can directly metabolize drugs into downstream metabolites with altered activity, clearance, and/or toxicity. Variations in the ability of each individual’s microbiome to metabolize drugs may be an underappreciated source of differences in clinical response. Complementary studies in humans and animal models are necessary to elucidate the mechanisms responsible and to test the feasibility of identifying microbiome-based biomarkers of treatment outcomes. SUMMARY: We propose that the predictive power of genetic testing could be improved by taking a more comprehensive view of human genetics that encompasses our human and microbial genomes. Furthermore, unlike the human genome, the microbiome is rapidly altered by diet, pharmaceuticals, and other interventions, providing the potential to improve patient care by re-shaping our associated microbial communities

Polymorphic Cis- and Trans-Regulation of Human Gene Expression

Using genetic and molecular analyses, we identified over 1,000 polymorphic regulators that regulate expression levels of human genes

Loss and Replenishment of Germline Stem Cells in Aging Drosophila melanogaster Testes

Stem cells have the unique and defining ability to replenish short-lived cell populations, such as skin, intestinal lining and sperm. We examined the loss and replacement of germline stem cells in Drosophila melanogaster testes. Using a lacZ transgene, we marked a limited number of germline stem cells per testis and calculated the percentage of testes retaining a marked stem cell over time. From these analyses, we calculated the half-life of individual germline stem cells to be 13 days. However, counting the number of germline stem cells per stem cell niche over time revealed that the actual decline in the population of germline stem cells was significantly less than the predicted decline based on a half-life of 13 days. These results suggest that while germline stem cells are lost over time, the niche is repopulated to replace lost stem cells, thereby increasing the functional lifetime of the testis

Mirror, mirror on the wall: which microbiomes will help heal them all?

BackgroundClinicians have known for centuries that there is substantial variability between patients in their response to medications-some individuals exhibit a miraculous recovery while others fail to respond at all. Still others experience dangerous side effects. The hunt for the factors responsible for this variation has been aided by the ability to sequence the human genome, but this just provides part of the picture. Here, we discuss the emerging field of study focused on the human microbiome and how it may help to better predict drug response and improve the treatment of human disease.DiscussionVarious clinical disciplines characterize drug response using either continuous or categorical descriptors that are then correlated to environmental and genetic risk factors. However, these approaches typically ignore the microbiome, which can directly metabolize drugs into downstream metabolites with altered activity, clearance, and/or toxicity. Variations in the ability of each individual's microbiome to metabolize drugs may be an underappreciated source of differences in clinical response. Complementary studies in humans and animal models are necessary to elucidate the mechanisms responsible and to test the feasibility of identifying microbiome-based biomarkers of treatment outcomes. We propose that the predictive power of genetic testing could be improved by taking a more comprehensive view of human genetics that encompasses our human and microbial genomes. Furthermore, unlike the human genome, the microbiome is rapidly altered by diet, pharmaceuticals, and other interventions, providing the potential to improve patient care by re-shaping our associated microbial communities